TSE:PLIProMetic Life Sciences Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding ProMetic Life Sciences Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add Add Compare Share Today's Range N/A50-Day RangeC$13.54MA: C$13.54▼C$13.5452-Week Range N/AVolume302 shsAverage Volume8,002 shsMarket CapitalizationC$315.66 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsInsider TradesHeadlinesSocial Media Prometic Life Sciences Inc. operates as a biopharmaceutical company with two drug discovery platforms that focuses on unmet medical needs in the field of fibrosis and orphan diseases. Its product pipeline includes PBI-4050, an orally active lead drug candidate for fibrosis; plasminogen, a biopharmaceutical for the treatment of congenital plasminogen deficiency; and intravenous immunoglobulin, a preparation of antibodies purified from plasma donations from healthy individuals. The company was founded in 1992 and is based in Laval, Canada.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for ProMetic Life Sciences. Previous Next 2.6 Community Rank Outperform VotesProMetic Life Sciences has received 442 “outperform” votes. (Add your “outperform” vote.)Underperform VotesProMetic Life Sciences has received 422 “underperform” votes. (Add your “underperform” vote.)Community SentimentProMetic Life Sciences has received 51.16% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about ProMetic Life Sciences and other stocks. Vote “Outperform” if you believe PLI will outperform the S&P 500 over the long term. Vote “Underperform” if you believe PLI will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldProMetic Life Sciences does not currently pay a dividend.Dividend GrowthProMetic Life Sciences does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ProMetic Life Sciences insiders have not sold or bought any company stock. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for ProMetic Life Sciences are expected to grow in the coming year, from C($2.66) to C$0.00 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ProMetic Life Sciences is -0.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ProMetic Life Sciences is -0.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next Analyst Opinion: 0.0Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.65 out of 5 stars Industry, Sector and Symbol Stock Exchange TSE Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolTSE:PLI Previous Symbol CUSIPN/A CIKN/A Webprometic.com Phone+1-450-7810115Debt Debt-to-Equity Ratio37.47 Current Ratio4.06 Quick Ratio3.66Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesC$39.91 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow3.94 Book ValueC$6.07 per share Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees487 Outstanding Shares23,313,000Market CapC$315.66 million Next Earnings DateN/A OptionableNot Optionable TSX:PLI Rates by TradingView Receive PLI News and Ratings via Email Sign-up to receive the latest news and ratings for PLI and its competitors with MarketBeat's FREE daily newsletter. ProMetic Life Sciences (TSE:PLI) Frequently Asked Questions Do Wall Street analysts recommend investors buy shares of ProMetic Life Sciences? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ProMetic Life Sciences in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for ProMetic Life Sciences. Has ProMetic Life Sciences been receiving favorable news coverage? Press coverage about PLI stock has trended very negative on Thursday, according to InfoTrie. InfoTrie rates the sentiment of news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. ProMetic Life Sciences earned a news impact score of -3.8 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View the latest news aboutProMetic Life Sciences. Who are some of ProMetic Life Sciences' key competitors? Some companies that are related to ProMetic Life Sciences include Concordia International (CXR), Clinuvel Pharmaceuticals (CUV), BELLUS Health (BLU), Aptose Biosciences (APS), Trillium Therapeutics (TRIL), PureTech Health (PRTC), Bellus Health (BLU), CEL-SCI (CVM), Oxford BioMedica (OXB), Cel-Sci (CVM), SIGA Technologies (SIGA), Paradigm Biopharmaceuticals (PAR), Biotest (BIO), Neptune Wellness Solutions (NEPT) and Silence Therapeutics (SLN). View all competitors. What other stocks do shareholders of ProMetic Life Sciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other ProMetic Life Sciences investors own include Nemaska Lithium (NMX), ProMetic Life Sciences (PFSCF), Bombardier, Inc. Class B (BBD.B), Crescent Point Energy (CPG), Sierra Wireless (SWIR), Baytex Energy (BTE), Dollarama (DOL), Parkland Fuel (PKI), Aurora Cannabis (ACB) and Resverlogix (RVX). Who are ProMetic Life Sciences' key executives? ProMetic Life Sciences' management team includes the following people: Mr. Kenneth H. Galbraith, CEO & Director (Age 56)Mr. Bruce Pritchard, International COO & Interim CFOMr. Patrick Sartore, Chief Legal Officer & Corp. Sec.Mr. Bruce Wendel, Chief Bus. Devel. Officer (Age 65)Dr. John Moran, Chief Medical Officer (Age 73) What is ProMetic Life Sciences' stock symbol? ProMetic Life Sciences trades on the Toronto Stock Exchange (TSX) under the ticker symbol "PLI." How do I buy shares of ProMetic Life Sciences? Shares of PLI and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade, and Charles Schwab. How big of a company is ProMetic Life Sciences? ProMetic Life Sciences has a market capitalization of C$0.00 and generates C$39.91 million in revenue each year. ProMetic Life Sciences employs 487 workers across the globe. What is ProMetic Life Sciences' official website? The official website for ProMetic Life Sciences is prometic.com. How can I contact ProMetic Life Sciences? ProMetic Life Sciences' mailing address is 440 Armand-Frappier Blvd Suite 300, LAVAL, QC H7V 4B4, Canada. The company can be reached via phone at +1-450-7810115. This page was last updated on 5/28/2020 by MarketBeat.com Staff
